Saol Therapeutics Announces Poster Presentation at the UMDF Mitochondrial Medicine 2025 Conference
Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the presentation of key findings from the Phase III trial of Sodium Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency...